Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine hydrochloride 2%)
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Pedis
Conditions
Tinea Pedis
Trial Timeline
Mar 1, 2015 → Dec 1, 2015
NCT ID
NCT02633813About Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine hydrochloride 2%)
Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine hydrochloride 2%) is a phase 3 stage product being developed by GenZum Life Sciences for Tinea Pedis. The current trial status is completed. This product is registered under clinical trial identifier NCT02633813. Target conditions include Tinea Pedis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02633813 | Phase 3 | Completed |
Competing Products
20 competing products in Tinea Pedis